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The eﬀects of restoration and maintenance of sinus rhythm by a combination of catheter
ablation and antiarrhythmic drugs (AADs) on atrial function in patients with chronic atrial
ﬁbrillation (AF) remain unknown. In 15 patients with chronic AF (>1 year), we attempted to
restore and maintain sinus rhythm by ablation targeting complex fractionated atrial
electrocardiograms (CFAEs) combined with pulmonary vein isolation with or without AADs.
Sinus rhythm was restored in all patients. At 17:7 7:2 months after AF ablation,
maintenance of sinus rhythm was achieved in 20% of patients without AADs and in 73.3% of
patients with AADs. The left atrial diameter decreased signiﬁcantly by 9:5 8:1% (P < 0:05)
during the 12-month followup. AADs did not have any adverse eﬀects. The aggressive
strategy for maintenance of sinus rhythm involving AF ablation and AADs potentially led to
recovery of structural changes in the LA in patients with chronic AF.
(J Arrhythmia 2009; 25: 63–69)
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Introduction
Atrial ﬁbrillation (AF) tends to be a chronic
condition, and thereby potentially leads to functional
and structural changes in both atria.1–7) Recent
studies have reported that various techniques, in-
cluding extensive circumferential pulmonary vein
isolation, AF ablation targeting complex fractionated
atrial electrograms (CFAEs), and stepwise ablation,
enable the restoration and maintenance of sinus
rhythm in patients with chronic AF.8–11) Regardless
of pharmacological or non-pharmacological therapy,
maintenance of sinus rhythm during long-term
follow-up has been shown to be associated with a
reduction in the left atrial (LA) diameter.11–14)
In contrast, the RACE trials revealed that antiar-
rhythmic drug (AAD) therapy alone is incapable of
fully maintaining sinus rhythm in patients with
persistent AF, and furthermore, can potentially lead
to adverse eﬀects.15) We attempted to restore and
maintain sinus rhythm in patients with chronic AF
(>1 year) by performing CFAE ablation combined
with pulmonary vein (PV) isolation with or without
AAD therapy. The aim of the present study was to
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assess whether our aggressive strategy beneﬁts
patients with chronic AF.
Methods
Study Population
Fifteen consecutive patients with chronic AF
referred for AF ablation were studied. In the present
study, chronic AF was deﬁned as AF lasting >1 year
(range, 1.5–13 years) and resistant to AAD and/or
DC cardioversion.
Preablation procedure
All patients were administered international nor-
malization ratio-based (2:5 > INR > 1:5) oral anti-
coagulant therapy for 2 months. The oral antico-
agulant therapy was substituted with heparin
infusion for 2 days before AF ablation. AAD and/
or  blocker therapy was discontinued at least 5 half-
lives before the procedure.
All patients were subjected to transesophageal
echocardiography to exclude the presence of a
thrombus in the LA, to measure the peak ﬂow
velocity at the ostium of the left atrial appendage,
and to observe the anatomy of the atrial septum.
Written informed consent was obtained from all
patients.
Swan-Ganz catheterization was performed before
and immediately after AF ablation in 10/15 patients
in order to assess the changes in the hemodynamic
parameters.
Ablation procedure
For recording and pacing, a decapolar catheter
(Inquiry Luma; Irvine Biomedical, USA) was placed
in the coronary sinus, and quadripolar catheters (M-
sweep; Daig, USA) were placed high in the right
atrium (RA) and the apex of the right ventricle.
An intracardiac phased-array ultrasound catheter
(Ultra ICE, Boston, USA) was placed in the RA to
guide trans-septal puncture. After trans-septal punc-
ture, heparin was infused intravenously as a bolus
of 5000U and was continuously administered to
achieve an activated clotting time (ACT) of 300
to 350 seconds during AF ablation. A 4-mm-tip
deﬂectable catheter (NaviStar, Biosense Webster,
USA) and 2 decapolar circular catheters (Lasso;
Biosense Webster, USA, and Optima; Irvine Bio-
medical, USA) were advanced to the LA and placed
in the ostium of each pulmonary vein for mapping
and ablation.
A 3D electroanatomical map of the LA, including
the PV ostia, the ostium of the LA appendage, and
the mitral annulus, was constructed using the
NaviStar catheter and a nonﬂuoroscopic navigation
system (CARTO; Biosense-Webster, USA). All sites
where CFAEs were identiﬁed during LA mapping
were tagged on the 3D CARTO map.
Based on the description of Nademanee et al.,10)
CFAEs were deﬁned as (1) atrial electrograms with
2 or more deﬂections and/or ﬂuctuation from the
baseline and/or continuous electrical activity over a
5-second period, or (2) atrial electrograms with very
short cycle length activity (<120msec) over a 5-
second period. Bipolar electrograms were recorded
using the NaviStar catheter and ﬁltered at a bandpass
of 30 to 500Hz.
Prior to application of radiofrequency (RF) en-
ergy, the borders of the esophageal lumen were
visualized by ﬂuoroscopy after the patient had
swallowed 10ml of a contrast medium (Gastrograﬁn;
Bayer Schering Pharma, Germany).
Ablation was performed using the Navistar cath-
eter and/or an 8-mm tip ablation catheter (Fantasis-
ta; Japan Lifeline, Japan) in the temperature-control
mode with guidance from the CARTO system, PV
angiograms, and the 3D-computed tomogram. For
PV isolation, RF was delivered to the LA-PV
junctions approximately 0.5 to 1 cm outside of the
PV ostium as deﬁned on angiography. For RF
delivery, we set a maximum temperature of 55 C
(50 C at the sites close to the esophagus) and a
maximum power of 25W (for the posterior aspect of
the left PV ostium close to the esophagus) to 35W
for up to 60 seconds. In sites where the RF output did
not rise up to 10W, the 8-mm tip ablation catheter
was used. The end point of PV isolation was
abolition or dissociation of electrical activity in all
the PVs.
The endpoint for CFAE ablation was conversion
of the CFAEs to discrete electrograms or approx-
imately >25% prolongation in the local cycle length
at each site. RF was delivered for 30 s at a maximum
temperature of 50 C and the maximum power
output of 30W to each site where CFAEs were
identiﬁed in the LA. Unless AF was terminated
through CFAE ablation in the LA, CFAE ablation
was additionally performed in the RA by the same
technique and up to the same endpoint as that for the
LA. If AF persisted even after CFAE ablation in both
atria, DC cardioversion was used to restore sinus
rhythm.
After restoration of sinus rhythm, the bidirectional
conduction block between the PV and LA was
conﬁrmed by circumferential pacing at the ostium of
each PV. If any residual PV-LA conduction was
found, RF was delivered to the conduction gap under
the guidance of circular catheters placed in the
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ostium of the PV to eliminate the PV-LA connec-
tions.
Transthoracic echocardiography
Transthoracic echocardiography was performed
immediately after AF ablation and then during 6–12
months of follow-up to assess the LA diameter,
LVEDD, and LVEF. LA diameter was measured in
the parasternal long axis view.
Follow-up
All patients were hospitalized for several days
after AF ablation for titration of oral anticoagulant
therapy to the international normalization ratio of 1.5
to 2.5 and were monitored telemetrically. After
discharge, all patients visited our outpatient clinic
at 2- to 4-week intervals. A standard ECG was
recorded at each visit. When patients presented with
any symptoms suggestive of paroxysmal AF recur-
rence, a 24-hour Holter ECG was additionally
performed. If there was paroxysmal AF recurrence,
AAD therapy was initiated after spontaneous AF
termination or DC cardioversion. If the paroxysmal
AF was not controlled by AAD within 3 months, the
patients were oﬀered further AF ablation. If the
patient had no symptoms at 3 months after AAD
therapy, they were oﬀered the option of discontinu-
ing AAD to exclude the possibility of false AF
recurrence in the blind period immediately after AF
ablation.
Statistical analysis
The continuous variables have been expressed as
the mean  standard deviation (SD). Analyses of
the changes in the hemodynamic parameters and
echocardiographic parameters were made conducted
using the paired t-test or the Wilcoxon signed-ranks
test. Pearson’s correlation coeﬃcient was used for
correlation analyses.
P < 0:05 was considered to be statistically sig-
niﬁcant.
Results
Study population
The baseline characteristics of the study subjects
are displayed in Table. Hypertensive heart disease
and dilated cardiomyopathy was present in 3 (20%)
and 2 patients (13%), respectively, and none of the
patients had ischemic heart disease.
The mean dilated LA diameter was 46:8 5:4mm
at baseline. The peak ﬂow velocity at the ostium of
the LA appendage reduced to 0:28 0:14m/s on the
transesophageal echocardiography.
In 6/15 (40%) patients, DC cardioversion failed to
restore sinus rhythm during a few months before AF
ablation.
Procedural outcome
The mean volume of the 3D LA geometry
constructed by the CARTO system was 108:1
24:6ml. The mean procedure time was 311 56
minutes (range, 270–480 minutes). More than 2
CFAE sites were recorded in all 15 patients. CFAEs
were identiﬁed most frequently around the PV
ostium (15 patients, 100%), followed by the anterior
wall (12 patients, 80%), the LA roof (12 patients,
80%), the LA septum (10 patients, 66.7%), perimi-
tral area (10 patients, 66.7%), and the posterior wall
(8 patients, 53.3%).
Figure 1 shows the AF ablation results from the
procedure up to 12 months of followup. The mean
followup duration was 17:7 7:2 months (range,
12–37 months).
In a single patient, AF was terminated during
CFAE ablation at the anterior wall of the LA.
Conversion of AF to polymorphic AFL was ob-
served in 1 patient. AFL could not be terminated by
the ablation procedures. Eventually, DC cardiover-
sion was performed to restore sinus rhythm after AF
ablation in the remaining 14 patients. Of these 14
patients, 2 had a history of AF for more than 5 years.
These 2 patients were administered 50mg of
ﬂecainide intravenously in order to facilitate DC
cardioversion, and oral ﬂecainide (100mg/day)
therapy was initiated to avoid early AF recurrence.
Paroxysmal AF recurred in 5 (33%) patients
during the ﬁrst 2 weeks after AF ablation and in 4
(26.7%) patients after this period. AF spontaneously
terminated and did not persist in all but 1 of the 9
patients in which DC cardioversion was performed.
Table Baseline Characterisitics of Patients
Age (years) 58.2  7.2
Gender (male/female) 14/1
AF duration (year) range 1–13
Failure in electrical cardioversion (%) 40.0, 6/15
NYHA classiﬁcation 1.3  0.6
Structural heart disease (%)
Hypertensive cardiomyopathy 20, 3/15
Dilated cardiomyopathy 13, 2/15
Ischemic heart disease 0
Echocardiographic data before AF ablation
LA diameter (mm) 46.8  5.4
LV end-diastolic dimension (mm) 50.6  5.0
LV ejection fraction (%) 51.6  5.0
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AAD therapy was initiated in these 9 patients—5 on
bepridil (50100mg/day), 1 on ﬂecainide (100mg/
day), 1 on pilsicainide (75mg/day), 1 on aprindine
(15mg/day), and 1 on amiodarone (200mg/dl). In 4
of these 9 patients, paroxysmal AF appeared fre-
quently. Of these, 3 patients underwent second
procedure (20%). One patient did not wish to
undergo the second procedure, and therefore was
given rate-control therapy.
At 12 months of follow-up after AF ablation,
paroxysmal AF was successfully controlled with and
without AAD in 11 (73.3%) patients and 3 (20%)
patients, respectively. There were no adverse eﬀects
from AAD during the follow-up period.
Complications
Over a total of 18 sessions, the following
complications were observed: deterioration of con-
gestive heart failure (n ¼ 1), transient ischemic
neurogenic attack (n ¼ 1), and partial right phrenic
nerve damage (n ¼ 1). All problems resolved com-
pletely within a few days.
Changes in the hemodynamic parameters after
AF ablation
In 10/15 patients who underwent AF ablation
(66.7%), the hemodynamic parameters before and
immediately after AF ablation were compared. The
changes in the mean heart rate (before and imme-
diately after AF ablation: 78:9 18:4/minute and
88:7 17:4/minute, respectively; P ¼ 0:1) and pul-
monary capillary wedge pressure (before and imme-
diately after AF ablation: 12:5 5:5mmHg and
12:3 6:4mmHg, respectively; P ¼ 0:89) were not
signiﬁcant. The cardiac index signiﬁcantly increased
immediately after AF ablation in all the study
subjects (before and immediately after AF ablation:
2:3 0:34 l/minute/m2 and 3:5 0:6 l/minute/m2,
respectively; P < 0:01). The stroke volume index
tended to increase (before and immediately after AF
ablation: 31:3 7:7ml/m2 and 38:4 7:2ml/m2,
respectively; P ¼ 0:05) (Figure 2).
Changes in the transthoracic echocardiographic
data after AF ablation
In 14 patients in whom sinus rhythm was main-
tained, the LA diameter signiﬁcantly decreased
from 46:8 5:4mm at baseline to 42:0 4:2mm
at 12 months of follow-up (P < 0:05) (Figure 3).
Neither the LV end-diastolic diameter nor the LV
ejection fraction changed during 12 months of
follow-up.
15 patients
CFAEs ablation plus PV isolation
1 SR during CFAEs ablation 14 AF/AFL after CFAEs ablation
14 SR after DC cardioversion
8 SR without AAD 7 PAF recurrence within 2 weeks after ablation
7 SR with AAD
6 AF recurrence at late stage
3 SR without AAD 11 SR with AAD
1 Discontinuation
of AAD 3 redo AF ablation
1 Chronic AF
with rate control
Figure 1 This tree shows in detail the AF ablation results for 15 patients with chronic atrial ﬁbrillation
(>1 year).
SR: sinus rhythm, AFL: atrial ﬂutter, AAD: antiarrhythmic drug therapy, PAF: paroxysmal AF.
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Discussion
We showed that CFAE ablation plus PV isolation
with DC cardioversion successfully restored sinus
rhythm in all 15 chronic AF cases; in 6 of these
cases, prior attempts of DC cardioversion had been
unsuccessful. CFAE ablation plus PV isolation
enabled the maintenance of sinus rhythm in all
patients, although 11/15 patients (73.3%) required
AAD therapy for 17:7 7:2 months. During the 12-
month follow-up period, LA diameter signiﬁcantly
decreased from the baseline value.
Signiﬁcance of CFAEs in the ablation strategy for
chronic AF
Recent studies have reported that PV isolation can
control AF without the need for AAD therapy by
eliminating the AF trigger in approximately 80% of
patients with paroxysmal AF.16) However, in patients
with a history of persistent AF, structural remodeling
possibly exists in the LA; therefore, substrate
modiﬁcation is considered to be necessary for
ablation of persistent AF.7,8,11–13)
Currently, various ablation techniques to modify
AF substrates have been proposed for treatment of
persistent AF.8–13) Nademanee et al. demonstrated
that ablation targeting CFAEs restored sinus rhythm
in 62% of patients with chronic AF and produced
a long-term success rate of 77%.10) In contrast, Oral
et al. revealed that ablation guided by CFAEs
resulted in the conversion of AF to sinus rhythm in
only 16% of patients with chronic AF, and then, the
rate of sinus rhythm was maintained at 57%.17) The
signiﬁcance of CFAEs in ablation for chronic AF
remains to be studied. In the present study, AF was
converted to sinus rhythm in 1 patient and to
polymorphic AFL in 1 patient during CFAE ablation
after PV isolation. Sinus rhythm was maintained
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Figure 2 Changes in the hemodynamic parameters before and immediately after the AF ablation.
A (upper left): Heart rate, B (upper right): Pulmonary capillary wedge pressure, C (lower left): Cardiac index,
D (lower right): Stroke volume index
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without the need for AAD therapy in 20% of the
patients and with AAD in 73.3% of the patients.
Although the AF conversion rate in this study was
similar to that reported by Oral et al.,17) the long-
term success rate without AAD was less than that
reported by other investigators.10,17) This discrep-
ancy might be derived from the diﬀerence in the
maximum power of RF used in both studies. They
used a maximum power of 70W as compared to the
maximum power of 35W used in the present study.
On the other hand, in the RACE trial in which a
strict protocol involving AAD with DC cardiover-
sion was adopted for the rhythm control group, sinus
rhythm was maintained in only 39% of the subjects
of that group.15) In the present study, maintenance of
sinus rhythm was observed in a greater percentage of
study subjects than in the rhythm control group of
the RACE trial. Accordingly, it was thought that
CFAE ablation plus PV isolation was potentially
more useful than AAD therapy alone for long-term
maintenance of sinus rhythm in chronic AF patients.
Signiﬁcance of maintenance of sinus rhythm in
the recovery of cardiac function
Haissaguerre et al. demonstrated that the restora-
tion and maintenance of sinus rhythm by catheter
ablation without AAD improved cardiac function,
including an improvement in LVEF and decrease in
the LA diameter among patients with congestive
heart failure and AF, mainly chronic AF.13)
In that study, patients with adequate rate control
also beneﬁted from catheter ablation; this ﬁnding
demonstrates that ablation produced the additional
hemodynamic beneﬁts from the restoration of sinus
rhythm rather than pharmacological rate control.
In the present study, we also revealed that the LA
diameter signiﬁcantly decreased by 9:5 8:1% dur-
ing 12-months follow-up period. Beukema et al.
revealed that AF recurrence after AF ablation was
associated with an increase in the LA diameter and
that there was a signiﬁcant relationship between the
success in the maintenance of sinus rhythm and the
decrease in the LA diameter.18) Since the LA
diameter was shown to decrease signiﬁcantly in the
present study, it was conceivable that our strategy
was truly eﬀective in maintaining sinus rhythm.
In the present study, AAD therapy had no adverse
eﬀects at the doses used during the follow-up period.
However, the AFFIRM and RACE trials have shown
that the adverse eﬀects of AAD oﬀset the beneﬁts of
the maintenance of sinus rhythm in cases where it is
used for the maintenance of sinus rhythm.15,19)
Therefore, careful attention should still be paid to
adverse eﬀects of AAD, particularly in the long run.
Conclusion
We observed that maintenance of sinus rhythm by
CFAE ablation plus PV isolation led to the recovery
of the structural changes in the LA, despite the fact
that AAD therapy was required in some cases.
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